---
title: "Aclaris Therapeutics, Inc. (ACRS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACRS.US.md"
symbol: "ACRS.US"
name: "Aclaris Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:38:44.521Z"
locales:
  - [en](https://longbridge.com/en/quote/ACRS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACRS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACRS.US.md)
---

# Aclaris Therapeutics, Inc. (ACRS.US)

## Company Overview

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.aclaristx.com](https://www.aclaristx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.72)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 136 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -52.93% |  |
| Net Profit YoY | 46.50% |  |
| P/B Ratio | 4.33 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 621503376.00 |  |
| Revenue | 8367000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -48.42% | E |
| Profit Margin | -832.58% | E |
| Gross Margin | -774.00% | E |
| Revenue YoY | -52.93% | E |
| Net Profit YoY | 46.50% | B |
| Total Assets YoY | 0.32% | D |
| Net Assets YoY | -0.29% | D |
| Cash Flow Margin | 74.94% | C |
| OCF YoY | -52.93% | E |
| Turnover | 0.04 | E |
| Gearing Ratio | 27.71% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Aclaris Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-52.93%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "46.50%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.33",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "621503376.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8367000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-48.42%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-832.58%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-774.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-52.93%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "46.50%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.32%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.29%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "74.94%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-52.93%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.71%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.92 | 181/189 | - | - | - |
| PB | 4.33 | 142/189 | 4.06 | 2.22 | 1.22 |
| PS (TTM) | 74.28 | 147/189 | 48.08 | 16.93 | 9.99 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 80% |
| Overweight | 1 | 10% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.50 |
| Highest Target | 16.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACRS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACRS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACRS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACRS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**